

COURSE FACULTY, IAS–USA STAFF, SCIENTIFIC LEADERSHIP BOARD, AND GOVERNANCE BOARD

FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as “commercial interests”) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months. View the [Faculty Financial Disclosure Policy](#).

ATLANTA, GA – MARCH 31, 2023

Course Presenters and Panelists	
Meredith Clement, MD Assistant Professor of Medicine Louisiana State University New Orleans, Louisiana	Dr Clement has received research grants paid to her institution from Gilead Sciences, Inc., ViiV Healthcare, and Janssen. She has served on Advisory Boards for ViiV Healthcare. (Updated 03/17/23)
Carlos del Rio, MD Distinguished Professor of Medicine Emory University Atlanta, Georgia	Dr Del Rio has served as a scientific advisor for Resverlogix. (Updated 05/23/22)
Joseph J. Eron, MD Professor of Medicine University of North Carolina at Chapel Hill School of Medicine Chapel Hill, North Carolina	Dr Eron has served as an ad hoc consultant to ViiV Healthcare, Merck & Co, Inc, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics (completed), ViiV Healthcare, and Gilead Sciences, Inc. (Updated 03/22/23)
Paul Goepfert, MD Professor of Medicine University of Alabama at Birmingham	Dr Goepfert served as a consultant for Janssen in 2021. (Updated 03/13/23)
Hyman Scott, MD, MPH Assistant Clinical Professor, School of Medicine University of California San Francisco	Dr Scott has no financial relationships with ineligible companies to disclose. (Updated 02/08/23)
Sandra A. Springer, MD Professor of Medicine Yale University New Haven, Connecticut	Dr Springer has received consulting fees from Alkermes Inc, and has received in-kind drug donations from Alkermes Inc (Vivitol) and Indivior (Sublocade) for NIH-sponsored research. (Updated 2/8/23)
Tiffany Walker, MD Assistant Professor Emory University School of Medicine Atlanta, Georgia	Dr Walker has no financial relationships with ineligible companies to disclose. (Updated 03/16/23)

IAS–USA CME Planners and Reviewers	
Jeffrey Lennox, MD Professor of Medicine Emory University Atlanta, Georgia	Dr Lennox has received payment for clinical trials from ViiV Healthcare. (Updated 03/24/23)
Michael S. Saag, MD Professor of Medicine, Emeritus Director, Center for AIDS Research Associate Dean for Global Health, School of Medicine University of Alabama at Birmingham	Dr Saag has received consulting or advisor fees from American Gene Technologies and TFF Pharmaceuticals. (Updated 02/08/23)
Donna M. Jacobsen Executive Director/President IAS–USA	Ms Jacobsen has no relevant financial affiliations with ineligible companies to disclose. (Updated 02/16/23)

IAS–USA Boards
The nonstaff members of the IAS–USA Scientific Advisory Board and Governance Board are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.